2026-07-04 · medications, qsymia, phentermine, topiramate, obesity medicine, prescription, weight-management · 20 min read

How much weight loss should I actually expect on Qsymia?

In the pivotal 56-week EQUIP trial (Allison 2012, Obesity) in adults with BMI ≥ 35, adults on top-dose Qsymia 15/92 mg lost a mean of 10.9% total body weight versus 1.6% on placebo. In CONQUER (Gadde 2011, The Lancet) in adults with BMI 27–45 and at least one comorbidity, the number was 9.8% on top-dose versus 1.4% on placebo. The SEQUEL extension (Garvey 2012, American Journal of Clinical Nutrition) followed CONQUER patients to 108 weeks and reported 10.5% mean weight loss maintained at 2 years on top-dose, with a 42% reduction in incident diabetes. Honest positioning: Qsymia produces roughly 80% of the weight loss seen on semaglutide 2.4 mg (~15% at 68 weeks in Wilding 2021 STEP-1) and roughly half of tirzepatide 15 mg (~21% at 72 weeks in Jastreboff 2022 SURMOUNT-1) — the best of the pre-GLP-1 oral options by a wide margin. Real-world discontinuation is meaningful: Yeh 2016 in JAMA Internal Medicine reported roughly 50% of Qsymia starters had stopped by 12 months, so the number you actually keep depends on tolerating the cognitive and paresthesia burden of topiramate through the first several weeks.

Who is Qsymia a good fit for?

Qsymia earns a place for three distinct groups. First, adults who cannot afford or tolerate a GLP-1 medication and want the strongest oral option available — the placebo-adjusted 9–11% weight loss is roughly twice what phentermine monotherapy or Contrave produce. Second, adults with comorbid migraine, because topiramate is independently effective for migraine prophylaxis and Qsymia can serve double duty. Third, adults for whom a stimulant plus GABAergic combination fits their eating pattern better than a GI-heavy GLP-1 — Qsymia targets noradrenergic satiety and glutamatergic palatability suppression rather than gastric emptying. Not a fit if you are pregnant or planning pregnancy (topiramate is a REMS-registered teratogen), if you have uncontrolled hypertension or hyperthyroidism, if you have a history of glaucoma, if you have a nephrolithiasis history, if you have taken an MAOI within 14 days, or if you have an active or prior eating disorder or history of stimulant misuse (phentermine is DEA Schedule IV).

Why does Qsymia have a REMS program?

Because the topiramate component causes a real, dose-dependent increase in first-trimester cleft lip and cleft palate (Chen 2009, American Journal of Obstetrics and Gynecology; Hernandez-Diaz 2012, Neurology). The absolute risk is small, but the relative risk versus unexposed pregnancies is roughly 2- to 3-fold, and the malformation window is early — often before a woman knows she is pregnant. The FDA 2012 approval labelling required a Risk Evaluation and Mitigation Strategy (REMS) program that mandates prescriber and pharmacy certification, patient counselling on teratogenicity, effective contraception for women of childbearing potential, and a pregnancy test before starting therapy and monthly during therapy. If pregnancy is confirmed at any point, Qsymia is discontinued immediately and the patient is referred for obstetric follow-up. The REMS program is why Qsymia is not something you can be prescribed casually in a general internal-medicine visit without the counselling architecture in place.

Is Qsymia the same as taking phentermine and topiramate separately?

Mechanistically, yes — the active ingredients are the same drugs that have been in generic use for decades. Clinically and legally, no. Qsymia is a fixed-dose extended-release combination that is FDA-approved for obesity with a specific titration schedule, an REMS program, and a documented dose-response curve. Prescribing phentermine and topiramate separately at Qsymia-equivalent doses is off-label for weight loss (topiramate has no FDA obesity indication as a monotherapy), often less consistent from a pharmacokinetic standpoint because immediate-release topiramate has a steeper cognitive side-effect curve than the extended-release formulation in Qsymia, and lacks the REMS teratogenicity architecture that is genuinely useful for women of childbearing potential. Some prescribers do use the separate generics as a cost-saving equivalent (Aronne 2013, Current Medical Research and Opinion, evaluated the head-to-head) — the evidence suggests roughly comparable weight loss but a higher discontinuation rate on the separate immediate-release formulation, driven mostly by topiramate paresthesia and cognitive side effects.

How is Qsymia dosed and titrated?

Qsymia is a once-daily morning tablet with four dose strengths: 3.75 mg phentermine / 23 mg topiramate ER (starting), 7.5/46 mg (standard maintenance), 11.25/69 mg (mid-dose), and 15/92 mg (top dose). The standard titration is weeks 1 and 2 at 3.75/23 mg, then weeks 3 onward at 7.5/46 mg. Escalation to 11.25/69 mg then 15/92 mg is reserved for patients with less than 3% weight loss at week 12 on the standard dose who want to try for further loss. The FDA stop rule (FDA 2012 labelling): if you have not lost at least 3% of baseline body weight by week 12 on the standard 7.5/46 mg dose, either escalate or discontinue; if you have not lost at least 5% of baseline body weight by week 12 on the top 15/92 mg dose, discontinue. Do not stop abruptly — topiramate carries a withdrawal seizure risk that is small but real, and the standard practice is to taper over 1 to 2 weeks even after short exposure.

What are the most common side effects?

In the EQUIP and CONQUER pivotal trials (Allison 2012; Gadde 2011), the most common adverse events on top-dose 15/92 mg versus placebo were paresthesia (~20% vs 2%), dry mouth (~19% vs 2%), constipation (~17% vs 6%), altered taste (dysgeusia; ~9% vs 1%), insomnia (~9% vs 5%), dizziness (~8% vs 3%), and word-finding difficulty and slowed cognitive processing (roughly 5–7% vs 1%). The cognitive side-effect profile is real and dose-dependent — Verrotti 2011 in Epilepsia catalogued it thoroughly in the topiramate epilepsy population. Small BP and heart-rate rises from the phentermine component are typical and require baseline and follow-up monitoring. Kidney stones occur in roughly 1 to 2% of Qsymia users versus roughly 0.5% at baseline (topiramate is a weak carbonic anhydrase inhibitor and produces mild metabolic acidosis and urinary citrate depletion), so hydration counselling is standard. Acute angle-closure glaucoma is a rare but serious idiosyncratic reaction — eye pain with vision change is a 911-level event.

Can I take Qsymia with a GLP-1 medication like Wegovy or Zepbound?

There is no direct pharmacokinetic interaction between Qsymia and semaglutide or tirzepatide, and the mechanisms are not identical — but they do overlap on the appetite-suppression axis, so the additive weight-loss benefit is often less than you would predict from stacking the two individual effects. In practice, most obesity-medicine specialists pick one drug and optimize it before considering combination, and the combination is off-label. If you are already on a GLP-1 and asking whether to switch to Qsymia, the honest framing is that you will trade about one-fifth of the weight loss for lower monthly cost, oral rather than injection dosing, and a different side-effect profile — but you will add a REMS teratogenicity constraint, a topiramate cognitive burden, a DEA Schedule IV constraint from phentermine, and a small paresthesia and kidney-stone risk. A common pattern is to use Qsymia for adults who cannot access or afford a GLP-1, or to use Qsymia as a bridge or a durable oral option in the pre- and post-GLP-1 windows.

Is Qsymia approved for adolescents?

Yes, as of June 2022 the FDA expanded the Qsymia indication to include adolescents age 12 and older with a BMI at or above the 95th percentile for age and sex (Kelly 2020 pediatric data supported the submission). This mirrors the age-12-and-older approvals for liraglutide and semaglutide in the adolescent obesity population. The pediatric protocol follows the adult titration (3.75/23 mg for 2 weeks, then 7.5/46 mg), with the same stop rule at 12 weeks and the same REMS teratogenicity requirements for adolescents of childbearing potential — adolescents on Qsymia require the same monthly pregnancy testing and effective-contraception counselling as adults. Cognitive side effects and school performance are important to monitor; oligohidrosis (reduced sweating) is also more relevant in the pediatric population per the topiramate prescribing information.

Qsymia (Phentermine-Topiramate) for Weight Loss: How the Combination Works and Why It Delivers More Than Phentermine Alone

Quick stats

• Placebo-adjusted weight loss at 56 weeks (Allison 2012 EQUIP, Obesity): mean 10.9% on top-dose Qsymia 15/92 mg vs 1.6% on placebo — the largest placebo-adjusted weight-loss result of any pre-GLP-1 oral obesity drug.
• Two-year maintenance (Garvey 2012 SEQUEL, AJCN): mean 10.5% weight loss maintained at 108 weeks; 42% relative reduction in incident diabetes.
• FDA-approved indication (FDA 2012): BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity; expanded in 2022 to adolescents 12 and older at or above the 95th percentile for age and sex.
• REMS teratogenicity program: topiramate first-trimester cleft lip / cleft palate signal — effective contraception, baseline and monthly pregnancy testing, immediate discontinuation on positive pregnancy test.
• DEA Schedule IV (inherited from phentermine): controlled-substance prescribing rules apply; MAOI 14-day washout required.
• Emergency red flags: acute eye pain with vision change (acute angle-closure glaucoma) — call 911; severe metabolic acidosis or hyperventilation — call 911; suspected overdose or accidental ingestion — Poison Control 1-800-222-1222.

The honest picture, in one paragraph

Qsymia produces roughly 9 to 11% placebo-adjusted weight loss on average over 56 weeks (Allison 2012 EQUIP; Gadde 2011 CONQUER) — best-in-class of the pre-GLP-1 oral options, roughly twice the effect size of phentermine monotherapy or Contrave, roughly 80% of the effect of semaglutide 2.4 mg (~15% at 68 weeks in Wilding 2021 STEP-1), and roughly half of tirzepatide 15 mg (~21% at 72 weeks in Jastreboff 2022 SURMOUNT-1). It works because the two active ingredients hit different mechanisms and stack additively (Kang 2010, Current Opinion in Investigational Drugs; Aronne 2010, Obesity): phentermine drives noradrenergic satiety and mild thermogenesis, and topiramate drives GABAergic and glutamatergic palatability suppression plus weak carbonic-anhydrase-inhibitor appetite modulation. It earns a place for adults who cannot afford or tolerate a GLP-1, adults with comorbid migraine (where topiramate is independently useful), and adults for whom a stimulant-plus-GABAergic mechanism outperforms the GI-heavy GLP-1 profile. It is not appropriate in pregnancy or in women of childbearing potential without an effective contraception plan and monthly pregnancy testing (the REMS teratogenicity program is genuine), in uncontrolled hypertension, hyperthyroidism, glaucoma, kidney-stone history, or within 14 days of an MAOI. Qsymia carries a REMS program for topiramate teratogenicity, a real cognitive and paresthesia burden, and a DEA Schedule IV constraint inherited from phentermine.

How Qsymia is dosed

Qsymia is a once-daily morning oral tablet in a fixed-dose extended-release phentermine plus topiramate formulation. It comes in four strengths — 3.75/23 mg, 7.5/46 mg, 11.25/69 mg, and 15/92 mg — and the titration schedule below is the FDA 2012 labelling.

FDA stop rule (FDA 2012 labelling): if you have not lost at least 3% of baseline body weight by week 12 on the standard 7.5/46 mg dose, either escalate to 15/92 mg or discontinue; if you have not lost at least 5% of baseline body weight by week 12 on the top 15/92 mg dose, discontinue. Do not stop abruptly — topiramate carries a small but real withdrawal seizure risk. Taper over 1 to 2 weeks by alternating day dosing before stopping.

Why Qsymia works (and does not) for weight

Four mechanistic threads explain the substantial and reproducible weight loss in EQUIP, CONQUER, and SEQUEL. The two drugs hit different targets, and the combination outperforms either monotherapy at every dose tested (Aronne 2010 head-to-head, Obesity).

1. Phentermine noradrenergic satiety

Phentermine is a sympathomimetic amine that increases synaptic norepinephrine and, to a lesser extent, dopamine and serotonin. In the hypothalamus, that noradrenergic tone reduces pre-meal hunger, shortens meal duration, and modestly raises resting energy expenditure — the classic thermogenic effect is small in absolute terms (roughly 50 to 100 kcal/day) but the appetite-suppression effect is what most patients experience as the drug “working”. This is the same effect phentermine monotherapy has been used for since 1959 (phentermine prescribing information) — see phentermine for weight loss for the monotherapy view.

2. Topiramate GABAergic, glutamatergic, and carbonic-anhydrase modulation

Topiramate is a broad-spectrum anticonvulsant whose weight-loss effect was first noticed as a side effect in epilepsy and migraine populations. Its mechanism is layered (Kang 2010, Current Opinion in Investigational Drugs): it potentiates GABA-A receptor signalling, blocks AMPA and kainate glutamate receptors, blocks voltage-gated sodium and calcium channels, and weakly inhibits carbonic anhydrase. Clinically, the observed effects are palatability suppression (foods that used to be pleasurable become bland), altered taste (dysgeusia — often reported as “carbonated drinks taste flat”), reduced snacking, and a mild energy-expenditure boost mediated by carbonic-anhydrase-related mild metabolic acidosis. The cognitive side-effect profile — word-finding difficulty, slowed processing, paresthesia — comes from the same channel-blockade mechanism (Verrotti 2011, Epilepsia).

3. Additive combination

The two mechanisms do not compete. Aronne 2010 in Obesity was the head-to-head trial that established the additive premise: phentermine plus topiramate produced greater weight loss than either monotherapy at every dose tested, without a proportional increase in cardiovascular or cognitive side effects. That result was the mechanistic justification for the fixed-dose product, and the EQUIP and CONQUER pivotal trials (Allison 2012; Gadde 2011) confirmed the effect at scale. Coffey 2012 in Current Medical Research and Opinion mapped the dose-response curve across the four strengths and confirmed that most of the tolerability signal (paresthesia, dysgeusia, cognitive) tracks the topiramate dose and most of the sympathomimetic signal (HR, BP, insomnia) tracks the phentermine dose.

4. What Qsymia is not

Qsymia is not a GLP-1 — the weight loss is roughly 80% the size of semaglutide 2.4 mg at 56 weeks and roughly half of tirzepatide 15 mg at 72 weeks. Qsymia is not a metabolic drug in the way GLP-1s and tirzepatide are — the diabetes-prevention signal in SEQUEL (Garvey 2012) is meaningful (42% reduction in incident T2D at 2 years), but Qsymia does not have direct cardiovascular outcome data and does not reduce A1c independent of weight loss the way a GLP-1 does. And Qsymia is not a substitute for a calorie deficit — every trial that produced the 9 to 11% mean weight loss also included a 500 kcal/day energy-deficit prescription and structured lifestyle counselling.

Dose-response and time-course

The trajectory is front-loaded: appetite reduction and palatability suppression appear within the first 2 to 4 weeks, weight-loss velocity peaks between months 3 and 6, and plateaus by month 12. The cognitive and paresthesia burden peaks in the first 4 to 8 weeks and often attenuates. Blood pressure, mood, hydration, and — for women of childbearing potential — pregnancy testing are monitored at every visit.

5-step Qsymia protocol

This is the pathway that matches the FDA 2012 labelling, the AACE 2016 Obesity Clinical Practice Guideline (Garvey), and the ADA 2024 Standards of Care. Every step is prescriber-mediated and REMS-registered pharmacies are required for dispensing.

Step 1: Confirm the indication

Qsymia is FDA-approved for adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes) — see the BMI calculator if you need to check. As of the June 2022 FDA update, Qsymia is also approved for adolescents 12 and older at or above the 95th percentile for age and sex (Kelly 2020). Positioning within the obesity-medicine armamentarium (Wadden 2020, JAMA): GLP-1 receptor agonists are first-line for most adults who qualify, and Qsymia is the strongest of the pre-GLP-1 orals — a reasonable choice when a GLP-1 is inaccessible, poorly tolerated, or when the phentermine plus topiramate mechanism is a better mechanistic fit (comorbid migraine, reward-driven eating that is more palatability-driven than hunger-driven).

Step 2: Screen for exclusions

Absolute contraindications and important precautions before prescribing:

• Pregnancy or planning pregnancy — REMS-registered topiramate teratogenicity (Chen 2009; Hernandez-Diaz 2012). Effective contraception and monthly pregnancy testing are required.
• Uncontrolled hypertension — the sympathomimetic component of phentermine will worsen it.
• Hyperthyroidism — additive tachycardia and metabolic acceleration.
• Glaucoma (particularly narrow-angle) — topiramate can precipitate acute angle-closure glaucoma; ophthalmology consultation is warranted if history is present.
• History of nephrolithiasis — a caution rather than an absolute contraindication; hydration counselling and citrate consideration are appropriate.
• Within 14 days of an MAOI (phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid) — risk of hypertensive crisis.
• Current or prior eating disorder — phentermine is a stimulant and adds abuse liability; topiramate can further destabilize eating patterns.
• History of stimulant misuse or dependence — phentermine is DEA Schedule IV.
• Metabolic acidosis or severe renal impairment — topiramate worsens acidosis.

Step 3: Baseline BP, mood, and pregnancy testing

Baseline vital signs (BP, HR), a mood screen (topiramate has a known depression and mood-lability signal), and a pregnancy test in every woman of childbearing potential are standard before the first dose. Under the REMS program, a pregnancy test is repeated monthly during therapy in that population and effective contraception is required for the entire duration of therapy. Baseline serum bicarbonate is worth checking in patients with any renal history because topiramate can produce mild metabolic acidosis that becomes clinically relevant if renal function is reduced.

Step 4: Titrate over 12 weeks

Start at 3.75/23 mg AM for 2 weeks — the tolerability check. Escalate to the 7.5/46 mg standard maintenance dose for weeks 3 through 12. Hydration counselling matters throughout: 2 to 3 L/day of water and avoidance of chronic dehydration reduce the kidney-stone risk (topiramate is a weak carbonic anhydrase inhibitor and depletes urinary citrate). The oligohidrosis (reduced sweating) that topiramate can cause is more relevant in hot climates and in pediatric patients, so heat-exposure counselling is worth including. If tolerability is limiting, hold escalation rather than abandoning the drug — paresthesia often improves with time.

Step 5: Assess at week 12 — the FDA stop rule

At week 12 on the 7.5/46 mg maintenance dose, reweigh. If less than 3% weight loss and further loss desired, escalate to 11.25/69 mg for 2 weeks, then to 15/92 mg top dose; reassess at week 12 on the top dose. If less than 5% weight loss at week 12 on the top 15/92 mg dose, discontinue per FDA labelling — continued exposure is not justified. Do not stop abruptly — taper over 1 to 2 weeks by alternate-day dosing to avoid topiramate withdrawal seizure. There is no formal upper limit on duration of therapy if the response is adequate and the patient tolerates the drug; ongoing BP, mood, and — for women of childbearing potential — monthly pregnancy testing remain the safety architecture.

What treatments actually do — comparison

Special situations

Women of childbearing potential

This is the single most important prescribing constraint. Topiramate is teratogenic (Chen 2009, American Journal of Obstetrics and Gynecology; Hernandez-Diaz 2012, Neurology) — first-trimester exposure raises the relative risk of cleft lip and cleft palate roughly 2- to 3-fold above baseline. The REMS program that accompanies Qsymia requires effective contraception (a documented plan, not an assumption), a baseline pregnancy test before the first dose, and a monthly pregnancy test during therapy. If a pregnancy test is positive at any point, Qsymia is discontinued immediately and the patient is referred for obstetric follow-up. Discussion of family planning is part of every prescribing visit for adults and adolescents of reproductive potential. The clinical bottom line: Qsymia is not a drug you casually restart if a woman has had a lapse in contraception. See birth control and weight changes for the surrounding contraception context.

Comorbid migraine

Topiramate is independently effective for migraine prophylaxis (it is FDA-approved as a monotherapy for migraine prevention). For adults whose comorbidities include chronic migraine and obesity, Qsymia can serve double duty — the same drug is doing both jobs, and no separate migraine prophylactic is needed. This is a genuine niche and one of the strongest population-specific arguments for Qsymia over Contrave or a GLP-1. See migraine and weight loss for the broader migraine and weight interaction.

Kidney-stone history

Topiramate is a weak carbonic anhydrase inhibitor and produces mild metabolic acidosis, urinary citrate depletion, and elevated urine pH — all of which favour calcium phosphate and calcium oxalate stone formation. In the EQUIP and CONQUER trials the incidence of nephrolithiasis was roughly 1 to 2% versus roughly 0.5% at baseline in placebo — small in absolute terms but real. A prior history of nephrolithiasis is a caution, not an absolute contraindication: aggressive hydration (2 to 3 L/day), avoidance of severe protein or oxalate loading, and — in patients with recurrent stones — consideration of potassium citrate supplementation are the mitigation steps. See kidney stones and weight loss for the broader kidney-stone context in obesity treatment.

Adolescents 12 and older

The June 2022 FDA expansion added adolescents at or above the 95th percentile for age and sex to the Qsymia indication (Kelly 2020 pediatric data). The titration schedule mirrors adults — 3.75/23 mg for 2 weeks, then 7.5/46 mg — and the 12-week stop rule applies. Cognitive side effects and school performance are important to monitor because the timing overlaps with academic testing. Oligohidrosis and heat-exposure counselling matter more in pediatric athletes. Adolescents of childbearing potential are on the same REMS teratogenicity monitoring as adults. See adolescent and teen weight management for the broader pediatric obesity picture.

Qsymia with — or switching to — a GLP-1

There is no direct pharmacokinetic interaction between Qsymia and semaglutide or tirzepatide. The mechanisms are not identical but they do overlap on the appetite-suppression axis, so stacking the two typically produces less than the sum of individual effects and adds a substantial tolerability and cost burden. Combination use is off-label. In practice, most obesity-medicine specialists pick one drug and optimize it before considering combination. When switching from Qsymia to a GLP-1, patients typically gain 3 to 5 additional percentage points of weight loss but lose the migraine benefit and add a GI burden. When switching from a GLP-1 to Qsymia (usually because of GLP-1 access, cost, or intolerance), the reverse trade-off applies. See prescription weight loss medications and weight loss injections near me for the broader comparison.

Post-bariatric surgery weight regain

Residual weight regain after bariatric surgery is common (see bariatric surgery overview for the broader picture), and Qsymia has a legitimate niche in that population — the surgical rearrangement often blunts the GI tolerance of a GLP-1, and an oral non-GLP-1 option is useful. The FDA labelling does not carve out a separate indication for post-bariatric patients, but the AACE 2016 obesity CPG (Garvey) acknowledges Qsymia as a reasonable option in that setting.

Red flags — when to call for help

Some symptoms on Qsymia are not routine and warrant same-day evaluation or emergency care.

• Acute eye pain with vision change, halos around lights, or nausea and vomiting — possible acute angle-closure glaucoma (topiramate can precipitate it). Call 911 and discontinue Qsymia; permanent vision loss can occur within hours.
• Severe hyperventilation, deep rapid breathing, confusion, or lethargy — possible severe metabolic acidosis. Call 911.
• Positive pregnancy test at any point during therapy — discontinue Qsymia immediately, notify prescriber the same day, and refer for obstetric follow-up (topiramate teratogenicity — first-trimester cleft lip / cleft palate risk).
• Sudden flank pain with hematuria — likely kidney stone. Urgent evaluation, imaging, and hydration; may require urology referral.
• Persistent word-finding difficulty, memory loss, or slowed cognitive processing impacting work or safety — consider dose reduction; if severe, discontinue and taper.
• New-onset seizure after abrupt discontinuation — do not stop Qsymia abruptly; taper over 1 to 2 weeks.
• Suspected overdose or accidental ingestion — call Poison Control at 1-800-222-1222 (US) immediately.

How this connects to the rest of the site

Qsymia sits in the obesity-medicine cluster and overlaps with several other guides. For the broader medication landscape, see prescription weight loss medications, phentermine for weight loss, Contrave for weight loss, and weight loss drug safety. For the GLP-1 comparison, see semaglutide for weight loss and tirzepatide for weight loss. For the migraine double-duty benefit, see migraine and weight loss. For the kidney-stone precaution, see kidney stones and weight loss. For the phentermine cardiovascular screening, see blood pressure and weight loss. For the surrounding care setting, see medical weight loss programs, weight loss injections near me, and telehealth weight loss.

Bottom line

Qsymia is the strongest oral weight-loss drug the FDA has approved to date. Its roughly 10% mean weight loss at 56 weeks — maintained at 2 years in SEQUEL — is roughly twice what phentermine monotherapy or Contrave produce and roughly 80% of what semaglutide 2.4 mg produces at a fraction of the monthly cost. It comes with real costs: a REMS teratogenicity program that is genuinely constraining for women of childbearing potential, a cognitive and paresthesia burden from topiramate that drives half of real-world discontinuation, a DEA Schedule IV constraint from phentermine, and a small but real kidney-stone and acute angle-closure glaucoma signal. It is a specialist-friendly drug, not a casual add-on. If those constraints fit you and your prescriber, the 9 to 11% mean weight loss it delivers — layered on top of the calorie-deficit and behavioural work that everything downstream depends on — is a real, useful, and durable result, and the migraine double-duty benefit is a strong argument in the right patient.

Qsymia FAQ

How much weight loss should I expect? Roughly 10% at 56 weeks on top-dose 15/92 mg (Allison 2012 EQUIP; Gadde 2011 CONQUER), maintained at 10.5% at 2 years (Garvey 2012 SEQUEL) — about 80% of semaglutide 2.4 mg and half of tirzepatide 15 mg.

Who is it best for? Adults who cannot afford or tolerate a GLP-1, adults with comorbid migraine (topiramate double duty), and adults for whom a stimulant plus GABAergic combination fits better than a GI-heavy GLP-1.

Who should not take it? Anyone pregnant or planning pregnancy, anyone with uncontrolled hypertension or hyperthyroidism, anyone with glaucoma or recurrent kidney stones, anyone with a current or prior eating disorder, and anyone within 14 days of an MAOI.

How is it dosed? 3.75/23 mg AM for 2 weeks, then 7.5/46 mg AM standard maintenance; escalate to 11.25/69 mg then 15/92 mg only if <3% loss at week 12 on the standard dose and further loss desired.

What is the FDA stop rule? Discontinue if <3% weight loss at week 12 on 7.5/46 mg (or escalate) and if <5% weight loss at week 12 on 15/92 mg. Taper over 1–2 weeks — do not stop abruptly (topiramate withdrawal seizure risk).

Why does it have a REMS program? Topiramate is a first-trimester teratogen (cleft lip / cleft palate). Effective contraception, baseline pregnancy test, and monthly pregnancy testing during therapy are required in women of childbearing potential.

Is Qsymia the same as taking phentermine and topiramate separately? Mechanistically yes; clinically and legally no. Qsymia is a fixed-dose ER combination with a titration schedule, REMS, and dose-response data. Separate generics are cheaper but lack the ER pharmacokinetics and REMS architecture.